General
Preferred name
FLUDARABINE
Synonyms
NSC 118218 ()
Fludarabinum ()
F-ara-A ()
FaraA, Fludarabinum, NSC 118218 ()
Fludarabine (NSC 118218) ()
NSC-118218 ()
Fludarabina ()
NSC-118218H ()
2-f-araa ()
2-fluorovidarabine ()
2-fluoro ara-a ()
Fluradosa ()
P&D ID
PD002993
CAS
21679-14-1
Tags
available
drug
Drug indication
B-cell acute lymphoblastic leukemia
Haematological malignancy
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Fludarabine is a chemotherapy drug used to treat blood cancers.
(GtoPdb)
PRICE
50
DESCRIPTION
Wnt/beta-catenin signaling inhibitor; axin stabilizer
(Tocris Bioactive Compound Library)
DESCRIPTION
Purine analog; inhibits DNA synthesis
(Tocriscreen Plus)
DESCRIPTION
Purine analog; inhibits DNA synthesis
(Tocriscreen Total)
DESCRIPTION
Fludarabine is a purine analog antimetabolite that inhibits DNA synthesis. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen.
(Enamine Bioactive Compounds)
DESCRIPTION
Fludarabine (Fludarabinum) is a fluorinated purine analog, an inhibitor of nucleic acid synthesis and an inhibitor of STAT1 activation. Fludarabine has antitumor activity and can be used for the treatment of leukemia and lymphoma.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
21
Organisms
0
Compound Sets
27
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
285.09
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
4
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
-1.84
TPSA
139.54
Fraction CSP3
0.5
Chiral centers
4.0
Largest ring
6.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Cell Biology
Target
Apoptosis
DNA synthesis
DNA/RNA Synthesis
Nucleoside antimetabolite/analog
STAT
STAT1
ADA, DCK, POLA1, RRM1, RRM2
DNA synthesis inhibitor
ADA
Apoptosis related,DNA/RNA Synthesis,Nucleoside Analog/Antimetabolite,STAT
Primary Target
DNA, RNA and Protein Synthesis
MOA
Inhibitor
Ribonucleotide Reductase inhibitor
Indication
chronic lymphocytic leukemia (CLL)
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
JAK/STAT Signaling
Stem Cells
Therapeutic Class
Anticancer Agents
Source data
